Compare Cassava Sciences Inc (FLNA) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Nuscale Power Corporation — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Nuscale Power Corporation trades at $7.6 (market cap $2.89B). The key difference: Nuscale Power Corporation is far larger — about 54.4× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| FLNA | SMR | |
|---|---|---|
Market Cap | $53.14M | $2.89B |
Sector | Health | Utilities |
52-Week High | $4.64 | $53.43 |
52-Week Low | $1.09 | $8.35 |
Enterprise Value | -$33.43M | $2.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
NuScale Power (SMR) trades at $7.54, down 12.22% in the last session amid ongoing operational challenges. The stock shows bearish technical signals with key support at $7.00. Fundamentally, the company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with negative margins and cash burn from operations. Analyst consensus remains optimistic with a $12.25 price target despite recent earnings misses.
The investment case hinges on SMR's first-mover advantage in nuclear technology and potential AI-driven power demand, but faces significant execution risk. With no commercial reactors yet operational and substantial cash burn, the stock represents high-risk speculation. Current valuation appears stretched given negative profitability metrics and uncertain revenue timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
